Patents by Inventor Ugur ESKIOCAK

Ugur ESKIOCAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190269776
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 5, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190224315
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10350292
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: July 16, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279039
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279038
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279040
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190125866
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 2, 2019
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190099488
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 4, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190060454
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: November 9, 2018
    Publication date: February 28, 2019
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190015508
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 17, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • TREATMENT FOR MELANOMA
    Publication number: 20170112865
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such combination in include MEK inhibitors, BRAF inhibitors and cardiac glycosides.
    Type: Application
    Filed: April 28, 2015
    Publication date: April 27, 2017
    Inventors: Sean J. MORRISON, Ugur ESKIOCAK
  • Treatment for melanoma
    Patent number: 9572828
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: February 21, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Sean Morrison, Ugur Eskiocak
  • Combination treatments for melanoma
    Patent number: 9561245
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 7, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Sean Morrison, Elena Piskounova, Ugur Eskiocak
  • TREATMENT FOR MELANOMA
    Publication number: 20150023915
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.
    Type: Application
    Filed: May 16, 2014
    Publication date: January 22, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Sean MORRISON, Ugur ESKIOCAK
  • TREATMENTS FOR MELANOMA
    Publication number: 20140080772
    Abstract: The present invention relates to mono- and combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include RO 31-8220, bafetinib, and cardiac glycosides.
    Type: Application
    Filed: September 5, 2013
    Publication date: March 20, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Sean MORRISON, Elena PISKOUNOVA, Ugur ESKIOCAK
  • COMBINATION TREATMENTS FOR MELANOMA
    Publication number: 20140066392
    Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.
    Type: Application
    Filed: September 5, 2013
    Publication date: March 6, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Sean MORRISON, Elena PISKOUNOVA, Ugur ESKIOCAK